Lei Tian

TL;DR: The currently available scRNA-seq technologies and analytical tools are summarized and the latest findings using sc RNA-seq that have substantially improved knowledge on the development of the cardiovascular system and the mechanisms underlying cardiovascular diseases are discussed.

TL;DR: This work uses scRNA-seq data generated by the Tabula Muris consortium to uncover transcriptional networks that maintain tissue-specific EC identity and to identify novel angiocrine and functional relationships between tissue- specific ECs.

TL;DR: It is found that clinically relevant doses of trastuzumab significantly impaired the contractile and calcium-handling properties of iPSC-CMs without inducing cardiomyocyte death or sarcomeric disorganization, and targeting the altered metabolism may be a promising therapeutic approach for trastzumab-induced cardiac dysfunction.

TL;DR: Massively parallel, droplet-based scRNA-seq allowed meticulous analysis of thousands of human iPSCs subjected to iPSC-EC differentiation, which showed inefficiency of the differentiation technique, which can be improved with further studies based on identification of molecular signatures that inhibit expansion of nonendothelial cell types.

TL;DR: The ability of clustered regularly interspaced short palindromic repeats/Cas9 genome-editing of carrier-specific iPSCs to elucidate both benign and pathogenic HCM functional phenotypes in a carrier- specific manner in a dish represents a promising VUS risk-assessment tool.